July 26, 2017 1:55 AM ET

Pharmaceuticals

Company Overview of Sound Pharmaceuticals, Inc.

Company Overview

Sound Pharmaceuticals, Inc., a biopharmaceutical company, develops prescription drugs that enable doctors and patients to prevent and treat hearing loss. It develops therapies for acquired forms of sensorineural hearing loss. The company was incorporated in 2001 and is based in Seattle, Washington.

4010 Stone Way North

Suite 120

Seattle, WA 98103

United States

Founded in 2001

Phone:

206-634-2559

Fax:

206-634-2342

Key Executives for Sound Pharmaceuticals, Inc.

Co-Founder and Chief Executive Officer
President and Director
Senior Director of Pharmaceutical Development
Senior Director of Clinical Operations
Compensation as of Fiscal Year 2017.

Sound Pharmaceuticals, Inc. Key Developments

Sound Pharmaceuticals Completes Enrollment on Meniere's Disease Clinical Trial

Sound Pharmaceuticals announced that it has completed enrollment on its first Meniere's Disease (MD) clinical trial. MD is a neurotologic disease that involves episodic vertigo, fluctuating sensorineural hearing loss, and intermittent or constant tinnitus, and is thought to be due to a swelling or inflammation of the inner ear. Patients with MD may also complain of aural fullness or pressure, and in extreme cases, may require surgery to decompress the inner ear. SPI-1005, an investigational new drug that mimics and induces Glutathione Peroxidase (GPx), has been shown to reduce the swelling or edema of the inner ear in animal studies involving acoustic trauma. In an earlier Phase 2 clinical trial, SPI-1005 was shown to prevent sensorineural hearing loss in young adults exposed to noise. These AAO-HNS presented findings have now been accepted for publication by a prestigious medical journal. Taken together, these results suggest a broad potential for SPI-1005 in the treatment of several types of sensorineural diseases of the inner ear. Currently, there are no FDA approved drug treatments for MD, or any other neurotologic disease.

Sound Pharmaceuticals, Inc. Announces $1.6 million Award from Cystic Fibrosis Foundation Therapeutics to Prevent and Treat the Hearing Loss and Tinnitus Associated with Antibiotic Use

Sound Pharmaceuticals, Inc. announced that it has been awarded up to $1.6 million from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT). The CFFT development award will support the initial testing of SPI-1005 in people with CF who are receiving tobramycin for the treatment of acute pulmonary exacerbations or lung infections. A leading side effect of tobramycin involves damage to the inner ear and is called ototoxicity. The Phase 1b STOP Ototoxicity clinical trial will examine the incidence and severity of hearing loss, tinnitus, dizziness or vertigo due to IV tobramycin treatment. SPI-1005 is a novel oral drug that is being developed to reduce the incidence and severity of sensorineural hearing loss and tinnitus in several disease states including ototoxicity, noise and Meniere's disease.

Sound Pharmaceuticals, Inc. Presents at 16th Annual Needham Healthcare Conference, Apr-04-2017 01:40 PM

Sound Pharmaceuticals, Inc. Presents at 16th Annual Needham Healthcare Conference, Apr-04-2017 01:40 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Jonathan Kil, Co-Founder and Chief Executive Officer.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sound Pharmaceuticals, Inc., please visit soundpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.